ERBB2 and breast cancer: Although PI3K/AKT/PTEN pathway inhibitors alpelisib and everolimus are used in clinical practice as combination partners with endocrine-based therapy, they have not shown an overall survival benefit in patients whose ER-positive, HER2-negative advanced breast cancer progressed on an aromatase inhibitor.